Aurora kinase A drives the evolution of resistance to third generation EGFR inhibitors in lung cancer

Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between drug responsiveness, tolerance and resistance, especially in the absence of pre-existing subclones, remains u...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Nat Med
Главные авторы: Shah, Khyati N., Bhatt, Roma, Rotow, Julia, Rohrberg, Julia, Olivas, Victor, Wang, Victoria E., Hemmati, Golzar, Martins, Maria M., Maynard, Ashley, Kuhn, Jonathan, Galeas, Jacqueline, Donnella, Hayley J., Kaushik, Swati, Ku, Angel, Dumont, Sophie, Krings, Gregor, Haringsma, Henry J., Robillard, Liliane, Simmons, Andrew D., Harding, Thomas C., McCormick, Frank, Goga, Andrei, Blakely, Collin M., Bivona, Trever G., Bandyopadhyay, Sourav
Формат: Artigo
Язык:Inglês
Опубликовано: 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324945/
https://ncbi.nlm.nih.gov/pubmed/30478424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0264-7
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы